The expiration of key patents on GLP-1 receptor agonists – a class of drugs initially developed for diabetes but increasingly used for weight loss, including popular medications like Ozempic and Wegovy – is triggering a wave of competition in the pharmaceutical market. Even as Novo Nordisk, the originator of these drugs, maintains a strong position, Indian pharmaceutical companies are poised to capitalize on the opportunity to produce and distribute more affordable generic versions. According to a recent report by Jefferies, an international brokerage firm, Sun Pharma, Lupin, and Torrent Pharma are best positioned to benefit from this shift, particularly within the Indian market.
The recent patent expiry has already spurred activity, with over 10 generic brands launching online and more than 40 expected to follow, encompassing both injectable and oral formulations. This increased competition is driving down prices, offering potential relief to patients who previously faced substantial costs for these medications. The dynamics of this emerging generic market, however, are complex, with initial supply shortages and heightened regulatory scrutiny adding layers of uncertainty.
The potential for significant cost savings is a key driver of this market shift. Ozempic, for example, previously cost between ₹8,800 and ₹11,175 per month in India, while Wegovy ranged from ₹10,850 to ₹16,400. Eli Lilly’s Mounjaro (tirzepatide), another GLP-1 receptor agonist, carried a price tag of ₹13,000 to ₹26,000 per injection, with each injection providing four monthly doses. Reuters reported in January 2024 that Novo Nordisk continues to grapple with supply constraints, further fueling demand for generics.
The Price of Access: Generics Enter the Market
Jefferies’ analysis indicates that current prices for generic injectable versions range from ₹1,290 to ₹4,500 per monthly dose. Natco and Glenmark are offering products at the lower end of this spectrum, while Dr. Reddy’s and Torrent Pharma are positioned at the higher end. Torrent Pharma currently holds the distinction of being the sole generic supplier of the oral formulation, offering it at a 30-50% discount compared to injectables. Zydus Lifesciences is also making a mark with a reusable multi-dose pen device, allowing for progressive dosage titration, a feature that could appeal to patients and healthcare providers alike.
Despite the build-up of inventory, Jefferies notes an unexpected shortage in online channels. Out of the initial 10 generic brands launched, only 3-4 remain available online, with the rest quickly selling out. This scarcity is attributed to a combination of factors, including inaccurate demand forecasting, limited initial supply allocated to online platforms, and increased regulatory oversight of the supply chain.
Regulatory Scrutiny and the Path Forward
The launch of these generic GLP-1 drugs is occurring under increased scrutiny from Indian regulators, who are focused on preventing unauthorized sales and ensuring ethical promotional practices. This heightened surveillance is intended to safeguard patient safety and maintain the integrity of the pharmaceutical supply chain. Companies are reportedly proceeding cautiously, testing the waters with demand and supply, and anticipating market stabilization in the coming months. The impact of these generic semaglutide launches on existing diabetes medications will also become clearer over time.
The success of these generic manufacturers isn’t solely about price. Jefferies highlights that these drugs are primarily prescribed by endocrinologists, internal medicine specialists, and, in some cases, cardiologists. Companies with strong relationships with these specialist physicians, and particularly those with a well-established presence in cardiovascular medicine, are likely to gain a competitive advantage. This is where Sun Pharma, Lupin, and Torrent Pharma are seen as having an edge.
Pharma Sector Gains as Competition Heats Up
The increased activity in the GLP-1 market has already had a positive impact on the Indian pharmaceutical sector. On Friday, the Nifty Pharma index was among the few sectoral indices to display gains on the National Stock Exchange of India, with stocks like Piramal Pharma and Mankind Pharma rising by as much as 2%. Jefferies maintains a ‘Buy’ rating for Alkem Laboratories, Emcure Pharmaceuticals, Lupin, Mankind Pharma, Sun Pharma, Torrent Pharma, and Zydus Lifesciences, while assigning an ‘Underperform’ rating to Cipla and Dr. Reddy’s Laboratories.
The potential market for these drugs in India is substantial. Current penetration rates remain low, with GLP-1 drugs reaching only about 5% of people with diabetes and 4% of those with obesity. Given that India has over 100 million people living with diabetes and an estimated 250 million individuals with obesity, the opportunity for growth is significant. The International Diabetes Federation provides comprehensive data on diabetes prevalence globally, highlighting the scale of the challenge.
Looking Ahead: Market Stabilization and Broader Access
The initial surge in demand and subsequent supply constraints suggest that the generic GLP-1 market in India is still in its early stages. As production ramps up and supply chains stabilize, prices are expected to become more competitive, and access to these medications should improve. The ongoing regulatory oversight will be crucial in ensuring the quality and safety of these generic products. The next few months will be critical in determining which companies emerge as long-term leaders in this rapidly evolving market.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical or investment advice. Consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment. Investment decisions should be made based on your own research and consultation with a financial advisor.
What are your thoughts on the increased availability of GLP-1 medications? Share your comments below, and please share this article with anyone who might discover it useful.
